Pancreatic Cancer Research

ResearcherUniversità Campus Bio-MedicoActive in the last 2 years

Michele Fiore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1889-4578; OpenAlex author ID A5020106424. Sources: ClinicalTrials.gov.

Their work

Papers
16
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2015: 1 paper · 2016: 1 trial · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. Conventionally Fractionated Radiotherapy (CFRT) Versus Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer: A Systematic Review and Me… Co-author DOI 10.3390/cancers18060971↗
  2. Exploratory PET/CT Radiomics for Predicting Early Progression in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/diagnostics16101499↗
  3. In silico evaluation of the potential of very high energy electrons delivered in both conventional and FLASH regimes for the SBRT treatment of pancreatic cance… Co-author DOI 10.1016/j.ejmp.2025.105076↗
  4. Pancreatic cancer care: Lighting the way with the torch of staging laparoscopy and advanced imaging. Co-author DOI 10.1016/j.ejso.2023.107257↗
  5. The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies. Co-author DOI 10.1097/js9.0000000000000755↗
  6. Ablative Five-Fraction Stereotactic Radiotherapy in Elderly Patients with Pancreatic Cancer: A Single Institution Experience. Co-author DOI 10.3390/jcm13247739↗
  7. Advances in pre-treatment evaluation of pancreatic ductal adenocarcinoma: a narrative review. Co-author DOI 10.21037/jgo-22-1034↗
  8. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PA… Co-author DOI 10.3390/curroncol30060427↗
  9. Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives. Co-author DOI 10.3390/biomedicines10092091↗
  10. CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. Co-author DOI 10.3389/fonc.2021.690580↗
  11. Definition of Local Recurrence Site in Resected Pancreatic Adenocarcinoma: A Multicenter Study (DOLORES-1). Co-author DOI 10.3390/cancers13123051↗
  12. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Co-author DOI 10.1002/cam4.3330↗
  13. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  14. A Bio-Imaging Signature as a Predictor of Clinical Outcomes in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers12082016↗
  15. Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic canc… Co-author DOI 10.1038/srep45845↗
  16. Patterns of radiotherapy practice for pancreatic cancer: Results of the Gastrointestinal Radiation Oncology Study Group multi-institutional survey. Co-author DOI 10.3892/or.2015.3955↗

Trials 1

  1. Induction FOLFIRINOX Followed by Chemoradiation in Locally Advanced Pancreatic Cancer Principal investigator NCT05399394↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sara Ramella · 10 shared papers, 2017–2026 · strength 1.78
  2. Damiano D. Caputo · 7 shared papers, 2017–2026 · strength 1.08
  3. Roberto Coppola · 6 shared papers, 2017–2024 · strength 0.81
  4. Vincenzo La Vaccara · 4 shared papers, 2021–2026 · strength 0.75
  5. Alessandro Coppola · 5 shared papers, 2020–2024 · strength 0.75
  6. Francesco Cellini · 4 shared papers, 2020–2026 · strength 0.56
  7. Nicola Simoni · 3 shared papers, 2020–2026 · strength 0.46
  8. Rolando Maria D’Angelillo · 3 shared papers, 2017–2024 · strength 0.45
  9. Domenico Genovesi · 3 shared papers, 2015–2026 · strength 0.38
  10. Alessio Giuseppe Morganti · 4 shared papers, 2015–2023 · strength 0.35
  11. Gabriella Macchia · 4 shared papers, 2015–2023 · strength 0.35
  12. Savino Cilla · 3 shared papers, 2020–2023 · strength 0.31
  13. Milly Buwenge · 3 shared papers, 2020–2023 · strength 0.31
  14. Alessandra Arcelli · 3 shared papers, 2020–2023 · strength 0.31
  15. Gian Carlo Mattiucci · 3 shared papers, 2015–2023 · strength 0.25
  16. Nunziata D’Abbiero · 1 shared paper, 2026 · strength 0.24
  17. Luca Nicosia · 1 shared paper, 2026 · strength 0.24
  18. Marcin Miszczyk · 1 shared paper, 2026 · strength 0.24
  19. Francesca De Felice · 1 shared paper, 2026 · strength 0.24
  20. Giampaolo Montesi · 1 shared paper, 2026 · strength 0.24
  21. Lidia Strigari · 2 shared papers, 2021–2023 · strength 0.23
  22. Renzo Mazzarotto · 2 shared papers, 2020–2023 · strength 0.21
  23. Mariacristina Di Marco · 2 shared papers, 2020–2023 · strength 0.21
  24. Angelica De Gregorio · 1 shared paper, 2025 · strength 0.20
  25. A. Sarti · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.